Recently, Fabi et al.’s study demonstrated that AKT inhibitors with DOX as a novel therapeutic combination strategy have a potential role in sensitizing cancer cells to DOX, which allows the upregulation of pro-apoptotic proteins the coordinated downregulation of anti-apoptotic regulators [18]. The gene discussed is AKT1; the disease is cancer.